Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)

Inclusion Criteria:

* 18 years of age or older
* Advanced or metastatic solid tumor malignancy
* ECOG performance status of less than or equal to 1
* Life expectancy of greater than 3 months
* At least 4 weeks must have elapsed between prior investigational therapy, chemotherapy, or radiotherapy, and the first dose of deforolimus
* Adequate hematological, hepatic and renal function
* Serum cholesterol less than or equal to 350 mg/dL and triglycerides less than or equal to 400 mg/dL
* Signed informed consent
* Women of childbearing potential must have a negative serum pregnancy test within 7 days of starting therapy and must use an approved contraceptive method from time of screening until 30 days after the last dose of study drug

Exclusion Criteria:

* Tumor location in close proximity to a major blood vessel
* History of brain metastases, spinal cord compression, or carcinomatous meningitis. Primary brain tumors (for example, glioblastoma) are allowed.
* New brain metastases, spinal cord compression, or leptomeningeal metastases on screening CT scan or MRI
* Hemoptysis or hematemesis within 28 days prior to entering the trial
* Clinical significant unexplained bleeding within 28 days prior to entering the trial
* Uncontrolled hypertension
* Proteinuria at screening
* Clinically significant cardiovascular disease
* Newly diagnosed or poorly controlled type 1 or 2 diabetes
* Active infection requiring prescribed intervention
* Other concurrent illness that, in the Investigator's judgement, would either compromise the patient's safety or interfere with the evaluation of the safety of the study drug
* Major surgery within 28 days before trial entry, or any incompletely healed surgical incision; minor surgery or procedures within 7 days
* Pregnant or breastfeeding
* Known allergy to macrolide antibiotics
* Known hypersensitivity to any component of bevacizumab
* Concurrent treatment with medications that strongly induce or inhibit cytochrome P450 (CYP3A)
* Known history of HIV sero-positivity
* Any condition in the Investigator's judgement that renders the patient unable to fully understand and provide informed consent and/or comply with the protocol